[go: up one dir, main page]

WO2006024949A3 - Controlled release dosage forms combining immediate release and sustained release of low-solubility drug - Google Patents

Controlled release dosage forms combining immediate release and sustained release of low-solubility drug Download PDF

Info

Publication number
WO2006024949A3
WO2006024949A3 PCT/IB2005/002825 IB2005002825W WO2006024949A3 WO 2006024949 A3 WO2006024949 A3 WO 2006024949A3 IB 2005002825 W IB2005002825 W IB 2005002825W WO 2006024949 A3 WO2006024949 A3 WO 2006024949A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
low
dosage forms
solubility drug
forms combining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002825
Other languages
French (fr)
Other versions
WO2006024949A2 (en
Inventor
Leah Elizabeth Appel
Dwayne Thomas Friesen
Scott Max Herbig
Avinash Govind Thombre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to MX2007002375A priority Critical patent/MX2007002375A/en
Priority to CA002578474A priority patent/CA2578474A1/en
Priority to BRPI0514416-7A priority patent/BRPI0514416A/en
Priority to EP05782784A priority patent/EP1789022A2/en
Priority to JP2007529035A priority patent/JP2008511609A/en
Publication of WO2006024949A2 publication Critical patent/WO2006024949A2/en
Publication of WO2006024949A3 publication Critical patent/WO2006024949A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A controlled release dosage form comprises an immediate release portion and an enteric coated sustained release core.
PCT/IB2005/002825 2004-08-31 2005-08-19 Controlled release dosage forms combining immediate release and sustained release of low-solubility drug Ceased WO2006024949A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2007002375A MX2007002375A (en) 2004-08-31 2005-08-19 Controlled release dosage forms combining immediate release and sustained release of low-solubility drug.
CA002578474A CA2578474A1 (en) 2004-08-31 2005-08-19 Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
BRPI0514416-7A BRPI0514416A (en) 2004-08-31 2005-08-19 controlled release dosage forms combining immediate release and controlled release of a low solubility drug
EP05782784A EP1789022A2 (en) 2004-08-31 2005-08-19 Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
JP2007529035A JP2008511609A (en) 2004-08-31 2005-08-19 Controlled release dosage forms combining rapid and sustained release of low-solubility drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60595504P 2004-08-31 2004-08-31
US60/605,955 2004-08-31

Publications (2)

Publication Number Publication Date
WO2006024949A2 WO2006024949A2 (en) 2006-03-09
WO2006024949A3 true WO2006024949A3 (en) 2006-05-04

Family

ID=35746910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002825 Ceased WO2006024949A2 (en) 2004-08-31 2005-08-19 Controlled release dosage forms combining immediate release and sustained release of low-solubility drug

Country Status (6)

Country Link
EP (1) EP1789022A2 (en)
JP (1) JP2008511609A (en)
BR (1) BRPI0514416A (en)
CA (1) CA2578474A1 (en)
MX (1) MX2007002375A (en)
WO (1) WO2006024949A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
JP5527921B2 (en) * 2006-12-22 2014-06-25 エスエス製薬株式会社 Oral solid composition concealing bitterness
BR112014008744A2 (en) 2011-10-21 2017-04-18 Takeda Pharmaceuticals Co prolonged release preparation, and methods for producing a prolonged release preparation, and for preventing and / or delaying the onset or suppressing progression of alzheimer's disease.
JPWO2014171542A1 (en) * 2013-04-19 2017-02-23 武田薬品工業株式会社 Controlled release formulation
WO2017039832A1 (en) * 2015-09-01 2017-03-09 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
EP4480495A3 (en) 2017-07-10 2025-06-18 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
GB201719769D0 (en) * 2017-11-28 2018-01-10 Cronin 3D Ltd Analytical device and methods of use
CN115707455B (en) * 2021-08-18 2025-03-14 越洋医药开发(广州)有限公司 Tablets allowing segmented release of sleep-regulating drugs and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
EP1027887A2 (en) * 1999-02-10 2000-08-16 Pfizer Products Inc. Matrix controlled release device
US20020009494A1 (en) * 1997-08-11 2002-01-24 Curatolo William J. Solid pharmaceutical dispersions with enhanced bioavailability
WO2004037190A2 (en) * 2002-10-25 2004-05-06 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2005020929A2 (en) * 2003-09-02 2005-03-10 Imran Ahmed Sustained release dosage forms of ziprasidone

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US20020009494A1 (en) * 1997-08-11 2002-01-24 Curatolo William J. Solid pharmaceutical dispersions with enhanced bioavailability
EP1027887A2 (en) * 1999-02-10 2000-08-16 Pfizer Products Inc. Matrix controlled release device
WO2004037190A2 (en) * 2002-10-25 2004-05-06 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2005020929A2 (en) * 2003-09-02 2005-03-10 Imran Ahmed Sustained release dosage forms of ziprasidone

Also Published As

Publication number Publication date
JP2008511609A (en) 2008-04-17
EP1789022A2 (en) 2007-05-30
BRPI0514416A (en) 2008-06-10
CA2578474A1 (en) 2006-03-09
WO2006024949A2 (en) 2006-03-09
MX2007002375A (en) 2007-04-23

Similar Documents

Publication Publication Date Title
IL180883A0 (en) Dosage forms with an enterically coated core tablet
AU2003221770A1 (en) Controlled release transdermal drug delivery
IL179140A0 (en) Antibody drug conjuates and methods
WO2005048923A3 (en) Extended release venlafaxine formulation
IL181555A0 (en) Method of assembly of drug delivery devices
IL216104A0 (en) Coated drug delivery formulations
WO2006024949A3 (en) Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
AU2003220472A1 (en) Modified release dosage form with two cores
ZA200705080B (en) Aminocarboxylic acid derivative and medicinal use thereof
PL1655026T3 (en) Solid pharmaceutical formulations comprising diacereine and meloxicam
WO2005105081A3 (en) Therapeutic formulations of desoxyepothilones
EP1791506A4 (en) Methods of device-assisted drug delivery
GB0406048D0 (en) Drug formulations
HK1090851A (en) Dosage forms with an enterically coated core tablet
TWI340642B (en) Acylaminothiazole derivatives, preparation and therapeutic application thereof
AU2002231176A1 (en) Sustained release drug delivery devices with coated drug cores
GB0426342D0 (en) Coupler capable of releasing development accelerator
AU2002231162A1 (en) Sustained release drug delivery devices with prefabricated permeable plugs
HK1116098A (en) Combination comprising an agent providing a signal, an implant material and a drug
AU2004903049A0 (en) Therapeutic conjugates for the delivery of polyionic drugs
AU2004901550A0 (en) Solid core phacoemulsification needle
AU2004905360A0 (en) Solid core phacoemulsification needle
HK1102349A (en) Antibody drug conjugates and methods
AU2004900098A0 (en) Flash and Sound Emitting Diversion Grenade
ZA200705996B (en) Medicament that is intended for oral administration, comprising a cyclooxygenase-2 inhibitor, and preparation method thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005782784

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007529035

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/002375

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2578474

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005782784

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0514416

Country of ref document: BR